| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | OpalX Therapeutics is an Australian biotechnology company focused on the development and commercialisation of advanced wound care and skin repair products derived from a proprietary Carica papaya extract technology. The company is developing a differentiated portfolio of topical products targeting skin damage, wound healing and dermatological conditions, supported by patent-protected extraction processes designed to preserve key bioactive compounds. OpalX's lead programs include OPAL X Active Skin Repair Cream for Stage 1 and 2 skin damage and OPAL X Gel for chronic and complex wound applications. The company's products are designed to address significant unmet clinical needs associated with ageing populations, diabetes, pressure injuries and impaired wound healing, while offering a naturally derived alternative to conventional wound care therapies. OpalX is planning a Phase II clinical trial in more than 40 aged-care residents at sites in Tasmania to evaluate OPAL X Active Skin Repair Cream for healing acute wounds, preventing skin injuries and improving skin quality. The trial is ready to commence pending Human Research Ethics Committee (HREC) approval. The resulting data is expected to support safety and efficacy claims for a Therapeutic Goods Administration (TGA) Listing on the Australian Register of Therapeutic Goods (ARTG). The company combines scientific innovation with a pragmatic commercial strategy focused on scalable manufacturing, regulatory progression and international market expansion. OpalX is establishing a Western Australian supply and manufacturing ecosystem incorporating local papaya growers, extraction partners, GMP manufacturing capabilities and analytical validation support. With an experienced leadership team spanning biotechnology, skin care and commercialisation, OpalX is positioning itself as an emerging player in the growing global advanced wound care and skin therapeutics market, with planned expansion into Asia Pacific. |
| Category: | Health & biotech |
| URL: | https://opalx.com.au |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2025 |
| Address: | 531 Hay St, Suite 5, Subiaco, Western Australia 6008, AU |
| State: | Western Australia |
| Overseas Operations: | No |
| X: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/opalx-therapeutics-pty-ltd/ |
| Founders: |
No items found
|
| Awards won: | |

